MD Biosciences was recently recognized by PharmaTech as a 'Top 10 most innovative CRO companies' for the European Market.
To learn more about recent technology advancements or have specific study inquiries, please contact us as we we would be happy to discuss with you.
#biotechnology #innovation #CRO
We recently published a publication demonstrating the utility of open field testing in combination with behavioral scoring in the pig peripheral neuritis trauma (PNT) model for pain. Combined together and applied in this model, they represent a powerful tool to assess the spontaneous behavior of pigs in response to pain. Rodent models are often used in pain research as they offer valuable data regarding underlying mechanisms contributing to pain, though they are limited in their translatability to human application. A pivotal benefit of using pig models is their increased translatability to the clinic considering the anatomical and physiological similarities pigs share with humans in comparison to rodents. This paper suggests that pig behavioral patterns are similarly translatable. MD Biosciences is proud to be a leader in neurology-related research, offering a variety of pig studies to enhance development in multiple therapeutic areas.
For more information regarding our pig study services, visit our website or contact us!
Topics: Pain, Stress, trauma pain, pain biomarkers, CNS imaging, Academic Researh, preclinical research, translational research, Behavioral Research, porcine model
MD Biosciences recognized in a paper published by Medtronic, a medical research company, to examine the efficacy of a sustained-release clonidine depot, placed in the wound bed, in a pig incisional pain model. To read the full paper, visit Dove Press Journal of Pain Research.
In addition to incisional pain models, other wound healing models offered at MD Biosciences are excisional woundings, heat wounds/burns, UV wounds and post-operative pain wounds. Contact us to discuss study-specific inquiries!
Proud to announce that the pig post operative pain model pioneered by our scientists was used and cited in a clinical study poster publication written by Heron Therapeutics to assess the synergistic effect of Bupivacaine and Meloxicam in HTX-011.
"Meloxicam and Bupivacaine combined in a single extended-release formulation (HTX-011) delivered at the wound site in a preclinical post-surgical pain model in pigs exhibited greater analgesia than either compound delivered alone within the same extended-release formulation; this finding was confirmed in an initial clinical trial in bunionectomy" (Heron Therapeutics, 2018).
To learn more about our rodent and pig post-operative pain models, visit our preclinical pain webpage or view our datasheet below.
Topics: Pain, post-operative pain, neuropathic pain, preclinical research
MB Biosciences is proud to announce our newly established electrophysiology capabilities suited for preclinical neuropathy research! Our lab has acquired the cutting-edge Dantec KEYPOINT Focus tool utilized to measure electrophysiological action potentials. Our scientists have applied these new capabilities in the assessment of Muscle Action Potential (measuring signals from the nerve to muscle) in rodent models of peripheral nerve injury. Using these capabilities, we can measure nerve regeneration, degeneration and protection in response to various treatments. This technology can be further applied to non-rodent species such are our pig translational pain models. Additionally, we are now offering measurement capabilities for Motor Action Potential with a specialized Renovo Neural paradigm—particularly useful for studies of EAE, MS, spinal cord injuries and CNS pain. Application of these capabilities specifically to EAE and MS models provide valuable insights into multiple areas of compound efficacy. View the graphs below to learn more about the ways in which using intraoperative techniques applied in the brain, peripheral nerve surgeries and spine has led us to developing models for monitoring impairment in neural activity. By empirically evaluating neural diseases and their physiological symptoms, we can effectively offer precise measurements for drug effect and treatment options.
To learn more about how this technology can be applied to specific study needs, please contact us.
In-vivo neurophysiology
Figure 1. A) CNS model - Transcranial electric motor evoked potentials (tcMEPs) were recorded from the bilateral tibialis anterior (TA) muscles using paired subdermal needle electrodes. TcMEP stimulating electrodes were placed anterior to the C3 and C4 scalp positions. B) Pain and sensory model - Somatosensory evoked potential (SSEP) - electrodes were placed along the medial aspect of each ankle at the malleoli for bipolar stimulation of the posterior tibial nerves (PTN). Somatosensory evoked potentials (SSEP) were recorded over the cerebral cortex using subdermal needle electrodes placed posterior to the C3 and C4 scalp positions. Recording electrodes were referenced to the FPz position on forehead. C) PNS model - Compound muscle action potential (CMAP) - recorded from the tibialis anterior muscle using paired subdermal needle electrodes. Stimulating electrodes were placed along the sciatic notch. Data were recorded from a Sprague Dawley rat.
A B C
Figure 2: tcMEP Recordings from TA muscle in a multiple sclerosis model. A A healthy potential recorded from naive mouse (C57). B) Desynchronized potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 1-2 (mild paralysis). Note multiple picks of potential, late latency for the main potential and extended duration of the total event. C) Small and weak potential recorded from a mouse treated with MOG demonstrating a clinical paralysis score of 3-4 (moderate paralysis).
Topics: Pain, neuropathic pain, preclinical research, Electrophysiology
MD Biosciences is proud to announce a recent addition to our extensive laboratory services and capabilities: The BD LSR FortessaTM X-20 Flow Cytometer offers the flexibility to support multiparametric (16+ color) analyses with advanced performance and consistency. These capabilities provide increased functionality for applications in preclinical, translational and clinical programs such as immunophenotyping of complex cellular populations, and analysis of cellular activation and proliferation states. Contact us to learn about our flow cytometry capabilities or discuss a study proposal with our scientific team!
Topics: clinical research, preclinical research, translational research, Biotechnology, immunophenotyping, flow cytometry
Oakdale, Minnesota USA
Nominated via the Minnesota State Dept. Of Employment and Economic Development (DEED), the Progress MN award, offered by Finance & Commerce, recognizes innovative companies that have provided major contributions to business, industrial growth and economic development in innovative and unique ways.
MD Biosciences US-site at the 4Front Technology & Office Campus in Oakdale, MN.
Taken from Finance and Commerce Website:
https://finance-commerce.com/2018/04/progress-mn-md-biosciences-inc/
April 6, 2018
Eddie Moradian, CEO of the family-owned MD Biosciences Inc., moved to Minnesota in 2008 from Switzerland to take over the company’s American operations.
Headquartered in Switzerland, MD Biosciences operates facilities and laboratories in that country, Israel and Minnesota.
The Minnesota location provides MD Biosciences with a central location and a highly dedicated and educated pool of researchers, health care centers and universities.
The company operates early-stage drug discovery and development laboratories in Minnesota. Labs at the two other locations often participate together in collaborative or fee-for-service pharmaceutical projects, Moradian said.
On a second front, MD Biosciences works closely with pharmaceutical and clinical laboratories in developing advanced clinical diagnostic tools and research products for inflammation, neuro-inflammation, immunological and oncological disease areas.
MD Biosciences has an in-depth expertise and scientific platform that attracts “novel” drug development work in the neurological, inflammatory and oncological disease areas, he said.
Such collaborations, along with internal developments, have resulted in a pipeline of non-opioid compounds for neuropathic pain, an advanced cancer program and blood-based diagnostic tool for a specific cancer, currently in clinical trials.
In 2016, Moradian partnered with Slumberland in the creation of an advanced, multi-technological incubator in Oakdale. “Incubology” offers dry and wet laboratory space, clean rooms and office space to companies in various areas, include biomolecule production, diagnostic processes, medical devices, nanotechnology and chemical synthesis.
“We believe that Incubology will soon grow to be an important regional anchor and seeding ground for new companies and technologies,” he said, “We are truly excited about what the future may bring.”
About MD Biosciences:
MD Biosciences is a leading provider of preclinical, translational and clinical-phase contract research services. Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of pharmaceutical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services.
About Incubology:
Incubology was founded to bring technology start-ups together in a shared environment. Members have the benefit of dedicated lab and office space in close proximity to other entrepreneurs from diverse disciplines including biotech, pharma, device, nano and chem. With innovative thinkers from a variety of tech industries in one setting, the opportunity for shared business resources and services is a definite advantage over single-unit space. And as part of a growth-oriented campus, the possibilities for the future are endless.
About Finance and Commerce:
Finance and Commerce is the only daily newspaper devoted exclusively to business in the Twin Cities (Minneapolis–Saint Paul) of Minnesota. Founded in 1887, it provides extensive coverage of Twin Cities business news in the areas of real estate, construction, technology, banking, energy, health care and advertising. It is the official newspaper for Hennepin County and the City of Minneapolis.
For more information, please contact MD Biosciences at: info-us@mdbiosciences.com
Topics: Biomarkers, drug development, clinical research, clinical diagnostics, preclinical research, translational research
Nes Ziona, Israel & Oakdale, MN, USA
MD Biosciences is pleased to announce OECD Good Laboratory Practices (GLP) Certification for it’s integrated histopathology and IHC facilities located at the Weizmann Science Park in Israel.
MD Biosciences Histopathology and IHC laboratories assist sponsors in the identification and development of clinically relevant biomarker assays and novel methods. The laboratories provide services for a wide variety of tissue types such as skin, joint, neuronal or others from human, porcine, rodent and other species.
This GLP certification for Histopathology and Toxicological Pathology follows GLP certification of MD Biosciences’ in vivo Preclinical Animal Research Facilities, as well as recognition according to Clinical Laboratory Improvement Amendment (CLIA) provisions for MD Biosciences Clinical Biomarker and Diagnostics Division.
About MD Biosciences:
MD Biosciences is a leading provider of clinical and preclinical contract research services. Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of preclinical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services.
For additional information related to our QC/QA divisions, please email info-us@mdbiosciences.com, Attention: Quality Division.
Topics: GLP Histopathology
